PharmaShots | Incisive News in 3 Shots

Subscribe Now

Advanced Non-Small Cell Lung Cancer

Mirati's Adagrasib (MRTX849) Receives the US FDA's Breakthrough Therapy Designation for Advanced Non-Small Cell Lung Cancer

Mirati's Adagrasib (MRTX849) Receives the US FDA's Breakthrough Therapy Designation for Advanced Non-Small Cell Lung Cancer

June 28, 2021

Takeda's Alunbrig (brigatinib) Receives MHLW's Approval as a 1L and 2L Treatment for ALK+ Advanced or Recurrent NSCLC

Takeda's Alunbrig (brigatinib) Receives MHLW's Approval as a 1L and 2L Treatment for ALK+ Advanced or Recurrent NSCLC

January 22, 2021

Takeda's Alunbrig (brigatinib) Receives EC's Approval as a 1L Treatment for ALK+ Advanced Non-Small Cell Lung Cancer

Takeda's Alunbrig (brigatinib) Receives EC's Approval as a 1L Treatment for ALK+ Advanced Non-Small Cell Lung Cancer

April 7, 2020

BMS Reports Pooled Five Year Results of Opdivo (nivolumab) in Two P-III Studies for Advanced Non-Small Cell Lung Cancer

BMS Reports Pooled Five Year Results of Opdivo (nivolumab) in Two P-III Studies for Advanced Non-Small Cell Lung Cancer

September 10, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us